Thalidomide-NH-C6-NH2 TFA is primarily utilized in biomedical research, particularly in the study of targeted protein degradation. It serves as a key component in the development of PROTACs (Proteolysis Targeting Chimeras), which are designed to selectively degrade disease-causing proteins. This compound is often employed in the synthesis of molecules that can bind to both a target protein and an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of the target protein via the proteasome. Its applications extend to cancer research, where it aids in the exploration of novel therapeutic strategies by degrading oncogenic proteins. Additionally, it is used in immunology studies to modulate immune responses by targeting specific proteins involved in inflammatory pathways. The compound’s role in drug discovery is significant, as it enables the development of innovative treatments for diseases that are currently difficult to manage with conventional therapies.